世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

抗悪性腫瘍療法の世界市場成長(現状と展望)2024-2030年


Global Anti-Neoplastic Therapy Market Growth (Status and Outlook) 2024-2030

LPI(LPインフォメーション)の最新調査によると、世界の抗新生物療法市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、抗新生物療法は2030年までに100万米ドルの再調整規模になる... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年6月21日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
116 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、世界の抗新生物療法市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、抗新生物療法は2030年までに100万米ドルの再調整規模になると予測され、レビュー期間中のCAGRは%である。
この調査レポートは、世界の抗新生物療法市場の成長可能性を明らかにしています。抗新生物療法は今後の市場でも安定した成長が期待される。しかし、抗新生物療法の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場参入企業は、抗新生物療法市場が提供する膨大な機会を活用するために、研究開発への投資、戦略的パートナーシップの構築、進化する消費者の嗜好に合わせた製品提供を行う必要がある。
抗新生物療法とは、新生物の発生を予防、抑制、阻止することを目的とした療法を指す。
世界の医薬品市場は、2022年には1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤がある。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。
主な特徴
抗新生物療法市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、抗新生物療法市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(例:化学療法剤、免疫療法剤)、地域別内訳などが含まれます。
市場促進要因と課題:政府規制、環境問題、技術進歩、消費者嗜好の変化など、抗悪性腫瘍剤市場の成長を促進する要因を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、初期コストの高さなど、業界が直面する課題も明らかにすることができる。
競合情勢:この調査レポートは、抗悪性腫瘍療法市場における競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれる。また、新興プレーヤーとその潜在的な市場への影響もハイライトできます。
技術開発:調査レポートは、抗新生物療法業界における最新の技術開発について掘り下げることができます。これには、抗新生物療法技術の進歩、抗新生物療法新規参入企業、抗新生物療法新規投資、抗新生物療法の将来を形作るその他の技術革新が含まれる。
川下企業の好み:本レポートは、抗悪性腫瘍剤市場における顧客の購買行動や採用動向を明らかにします。このレポートには、顧客の購買決定や抗悪性腫瘍療法製品の嗜好に影響を与える要因が含まれています。
政府の政策とインセンティブこの調査レポートは、政府の政策やインセンティブが抗新生物療法市場に与える影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、および抗新生物療法市場の促進を目的としたその他の措置の評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価する。
環境への影響と持続可能性調査レポートは、抗新生物療法市場の環境影響と持続可能性の側面を評価します。
市場予測と将来展望:実施した分析に基づき、調査レポートは抗新生物療法産業の市場予測と展望を提供します。これには、市場規模、成長率、地域別動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、抗新生物療法市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
抗新生物療法市場はタイプ別と用途別に分類される。2019年から2030年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を提供します。
タイプ別セグメント
化学療法剤
免疫治療薬
個別化医療
用途別セグメント
病院
診療所
癌リハビリセンター
外来手術センター
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
アムジェン社
アストラゼネカ
バイエル
ジョンソン・エンド・ジョンソン
メルク・アンド・カンパニー
ファイザー
F.ホフマン・ラ・ロシュ社
イーライリリー・アンド・カンパニー
テバ・ファーマシューティカル・インダストリーズ社
ベーリンガーインゲルハイム
アスペン・ファーマケア・ホールディングス
アッヴィ


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anti-Neoplastic Therapy Market Size 2019-2030
2.1.2 Anti-Neoplastic Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Anti-Neoplastic Therapy Segment by Type
2.2.1 Chemotherapeutic Agents
2.2.2 Immunotherapeutic Agents
2.2.3 Personalized Medicine
2.3 Anti-Neoplastic Therapy Market Size by Type
2.3.1 Anti-Neoplastic Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Anti-Neoplastic Therapy Market Size Market Share by Type (2019-2024)
2.4 Anti-Neoplastic Therapy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Cancer Rehabilitation Centers
2.4.4 Ambulatory Surgical Centers
2.5 Anti-Neoplastic Therapy Market Size by Application
2.5.1 Anti-Neoplastic Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Anti-Neoplastic Therapy Market Size Market Share by Application (2019-2024)
3 Anti-Neoplastic Therapy Market Size by Player
3.1 Anti-Neoplastic Therapy Market Size Market Share by Players
3.1.1 Global Anti-Neoplastic Therapy Revenue by Players (2019-2024)
3.1.2 Global Anti-Neoplastic Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Anti-Neoplastic Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Anti-Neoplastic Therapy by Regions
4.1 Anti-Neoplastic Therapy Market Size by Regions (2019-2024)
4.2 Americas Anti-Neoplastic Therapy Market Size Growth (2019-2024)
4.3 APAC Anti-Neoplastic Therapy Market Size Growth (2019-2024)
4.4 Europe Anti-Neoplastic Therapy Market Size Growth (2019-2024)
4.5 Middle East & Africa Anti-Neoplastic Therapy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Anti-Neoplastic Therapy Market Size by Country (2019-2024)
5.2 Americas Anti-Neoplastic Therapy Market Size by Type (2019-2024)
5.3 Americas Anti-Neoplastic Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-Neoplastic Therapy Market Size by Region (2019-2024)
6.2 APAC Anti-Neoplastic Therapy Market Size by Type (2019-2024)
6.3 APAC Anti-Neoplastic Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Anti-Neoplastic Therapy by Country (2019-2024)
7.2 Europe Anti-Neoplastic Therapy Market Size by Type (2019-2024)
7.3 Europe Anti-Neoplastic Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Anti-Neoplastic Therapy by Region (2019-2024)
8.2 Middle East & Africa Anti-Neoplastic Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Anti-Neoplastic Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Anti-Neoplastic Therapy Market Forecast
10.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030)
10.1.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030)
10.1.2 Americas Anti-Neoplastic Therapy Forecast
10.1.3 APAC Anti-Neoplastic Therapy Forecast
10.1.4 Europe Anti-Neoplastic Therapy Forecast
10.1.5 Middle East & Africa Anti-Neoplastic Therapy Forecast
10.2 Americas Anti-Neoplastic Therapy Forecast by Country (2025-2030)
10.2.1 United States Anti-Neoplastic Therapy Market Forecast
10.2.2 Canada Anti-Neoplastic Therapy Market Forecast
10.2.3 Mexico Anti-Neoplastic Therapy Market Forecast
10.2.4 Brazil Anti-Neoplastic Therapy Market Forecast
10.3 APAC Anti-Neoplastic Therapy Forecast by Region (2025-2030)
10.3.1 China Anti-Neoplastic Therapy Market Forecast
10.3.2 Japan Anti-Neoplastic Therapy Market Forecast
10.3.3 Korea Anti-Neoplastic Therapy Market Forecast
10.3.4 Southeast Asia Anti-Neoplastic Therapy Market Forecast
10.3.5 India Anti-Neoplastic Therapy Market Forecast
10.3.6 Australia Anti-Neoplastic Therapy Market Forecast
10.4 Europe Anti-Neoplastic Therapy Forecast by Country (2025-2030)
10.4.1 Germany Anti-Neoplastic Therapy Market Forecast
10.4.2 France Anti-Neoplastic Therapy Market Forecast
10.4.3 UK Anti-Neoplastic Therapy Market Forecast
10.4.4 Italy Anti-Neoplastic Therapy Market Forecast
10.4.5 Russia Anti-Neoplastic Therapy Market Forecast
10.5 Middle East & Africa Anti-Neoplastic Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Anti-Neoplastic Therapy Market Forecast
10.5.2 South Africa Anti-Neoplastic Therapy Market Forecast
10.5.3 Israel Anti-Neoplastic Therapy Market Forecast
10.5.4 Turkey Anti-Neoplastic Therapy Market Forecast
10.5.5 GCC Countries Anti-Neoplastic Therapy Market Forecast
10.6 Global Anti-Neoplastic Therapy Forecast by Type (2025-2030)
10.7 Global Anti-Neoplastic Therapy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Information
11.1.2 Amgen Inc. Anti-Neoplastic Therapy Product Offered
11.1.3 Amgen Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Amgen Inc. Main Business Overview
11.1.5 Amgen Inc. Latest Developments
11.2 AstraZeneca plc
11.2.1 AstraZeneca plc Company Information
11.2.2 AstraZeneca plc Anti-Neoplastic Therapy Product Offered
11.2.3 AstraZeneca plc Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 AstraZeneca plc Main Business Overview
11.2.5 AstraZeneca plc Latest Developments
11.3 Bayer AG
11.3.1 Bayer AG Company Information
11.3.2 Bayer AG Anti-Neoplastic Therapy Product Offered
11.3.3 Bayer AG Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bayer AG Main Business Overview
11.3.5 Bayer AG Latest Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Anti-Neoplastic Therapy Product Offered
11.4.3 Johnson & Johnson Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Johnson & Johnson Main Business Overview
11.4.5 Johnson & Johnson Latest Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Information
11.5.2 Merck & Co., Inc. Anti-Neoplastic Therapy Product Offered
11.5.3 Merck & Co., Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Merck & Co., Inc. Main Business Overview
11.5.5 Merck & Co., Inc. Latest Developments
11.6 Pfizer Inc.
11.6.1 Pfizer Inc. Company Information
11.6.2 Pfizer Inc. Anti-Neoplastic Therapy Product Offered
11.6.3 Pfizer Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Pfizer Inc. Main Business Overview
11.6.5 Pfizer Inc. Latest Developments
11.7 F. Hoffmann-La Roche Ltd.
11.7.1 F. Hoffmann-La Roche Ltd. Company Information
11.7.2 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Product Offered
11.7.3 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.7.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Information
11.8.2 Eli Lilly and Company Anti-Neoplastic Therapy Product Offered
11.8.3 Eli Lilly and Company Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Eli Lilly and Company Main Business Overview
11.8.5 Eli Lilly and Company Latest Developments
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Teva Pharmaceutical Industries Ltd. Company Information
11.9.2 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Product Offered
11.9.3 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.9.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Anti-Neoplastic Therapy Product Offered
11.10.3 Boehringer Ingelheim Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Boehringer Ingelheim Main Business Overview
11.10.5 Boehringer Ingelheim Latest Developments
11.11 Aspen Pharmacare Holdings Limited
11.11.1 Aspen Pharmacare Holdings Limited Company Information
11.11.2 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Product Offered
11.11.3 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Aspen Pharmacare Holdings Limited Main Business Overview
11.11.5 Aspen Pharmacare Holdings Limited Latest Developments
11.12 AbbVie Inc.
11.12.1 AbbVie Inc. Company Information
11.12.2 AbbVie Inc. Anti-Neoplastic Therapy Product Offered
11.12.3 AbbVie Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 AbbVie Inc. Main Business Overview
11.12.5 AbbVie Inc. Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Anti-Neoplastic Therapy market size was valued at US$ million in 2023. With growing demand in downstream market, the Anti-Neoplastic Therapy is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Anti-Neoplastic Therapy market. Anti-Neoplastic Therapy are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Anti-Neoplastic Therapy. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Anti-Neoplastic Therapy market.
Anti-neoplastic therapy refers to the therapy which aims to prevent, inhibit or halt the development of a neoplasm.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Anti-Neoplastic Therapy market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Anti-Neoplastic Therapy market. It may include historical data, market segmentation by Type (e.g., Chemotherapeutic Agents, Immunotherapeutic Agents), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Anti-Neoplastic Therapy market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Anti-Neoplastic Therapy market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Anti-Neoplastic Therapy industry. This include advancements in Anti-Neoplastic Therapy technology, Anti-Neoplastic Therapy new entrants, Anti-Neoplastic Therapy new investment, and other innovations that are shaping the future of Anti-Neoplastic Therapy.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Anti-Neoplastic Therapy market. It includes factors influencing customer ' purchasing decisions, preferences for Anti-Neoplastic Therapy product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Anti-Neoplastic Therapy market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Anti-Neoplastic Therapy market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Anti-Neoplastic Therapy market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Anti-Neoplastic Therapy industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Anti-Neoplastic Therapy market.
Market Segmentation:
Anti-Neoplastic Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Chemotherapeutic Agents
Immunotherapeutic Agents
Personalized Medicine
Segmentation by application
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen Inc.
AstraZeneca plc
Bayer AG
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim
Aspen Pharmacare Holdings Limited
AbbVie Inc.



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Anti-Neoplastic Therapy Market Size 2019-2030
2.1.2 Anti-Neoplastic Therapy Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Anti-Neoplastic Therapy Segment by Type
2.2.1 Chemotherapeutic Agents
2.2.2 Immunotherapeutic Agents
2.2.3 Personalized Medicine
2.3 Anti-Neoplastic Therapy Market Size by Type
2.3.1 Anti-Neoplastic Therapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Anti-Neoplastic Therapy Market Size Market Share by Type (2019-2024)
2.4 Anti-Neoplastic Therapy Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Cancer Rehabilitation Centers
2.4.4 Ambulatory Surgical Centers
2.5 Anti-Neoplastic Therapy Market Size by Application
2.5.1 Anti-Neoplastic Therapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Anti-Neoplastic Therapy Market Size Market Share by Application (2019-2024)
3 Anti-Neoplastic Therapy Market Size by Player
3.1 Anti-Neoplastic Therapy Market Size Market Share by Players
3.1.1 Global Anti-Neoplastic Therapy Revenue by Players (2019-2024)
3.1.2 Global Anti-Neoplastic Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Anti-Neoplastic Therapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Anti-Neoplastic Therapy by Regions
4.1 Anti-Neoplastic Therapy Market Size by Regions (2019-2024)
4.2 Americas Anti-Neoplastic Therapy Market Size Growth (2019-2024)
4.3 APAC Anti-Neoplastic Therapy Market Size Growth (2019-2024)
4.4 Europe Anti-Neoplastic Therapy Market Size Growth (2019-2024)
4.5 Middle East & Africa Anti-Neoplastic Therapy Market Size Growth (2019-2024)
5 Americas
5.1 Americas Anti-Neoplastic Therapy Market Size by Country (2019-2024)
5.2 Americas Anti-Neoplastic Therapy Market Size by Type (2019-2024)
5.3 Americas Anti-Neoplastic Therapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-Neoplastic Therapy Market Size by Region (2019-2024)
6.2 APAC Anti-Neoplastic Therapy Market Size by Type (2019-2024)
6.3 APAC Anti-Neoplastic Therapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Anti-Neoplastic Therapy by Country (2019-2024)
7.2 Europe Anti-Neoplastic Therapy Market Size by Type (2019-2024)
7.3 Europe Anti-Neoplastic Therapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Anti-Neoplastic Therapy by Region (2019-2024)
8.2 Middle East & Africa Anti-Neoplastic Therapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Anti-Neoplastic Therapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Anti-Neoplastic Therapy Market Forecast
10.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030)
10.1.1 Global Anti-Neoplastic Therapy Forecast by Regions (2025-2030)
10.1.2 Americas Anti-Neoplastic Therapy Forecast
10.1.3 APAC Anti-Neoplastic Therapy Forecast
10.1.4 Europe Anti-Neoplastic Therapy Forecast
10.1.5 Middle East & Africa Anti-Neoplastic Therapy Forecast
10.2 Americas Anti-Neoplastic Therapy Forecast by Country (2025-2030)
10.2.1 United States Anti-Neoplastic Therapy Market Forecast
10.2.2 Canada Anti-Neoplastic Therapy Market Forecast
10.2.3 Mexico Anti-Neoplastic Therapy Market Forecast
10.2.4 Brazil Anti-Neoplastic Therapy Market Forecast
10.3 APAC Anti-Neoplastic Therapy Forecast by Region (2025-2030)
10.3.1 China Anti-Neoplastic Therapy Market Forecast
10.3.2 Japan Anti-Neoplastic Therapy Market Forecast
10.3.3 Korea Anti-Neoplastic Therapy Market Forecast
10.3.4 Southeast Asia Anti-Neoplastic Therapy Market Forecast
10.3.5 India Anti-Neoplastic Therapy Market Forecast
10.3.6 Australia Anti-Neoplastic Therapy Market Forecast
10.4 Europe Anti-Neoplastic Therapy Forecast by Country (2025-2030)
10.4.1 Germany Anti-Neoplastic Therapy Market Forecast
10.4.2 France Anti-Neoplastic Therapy Market Forecast
10.4.3 UK Anti-Neoplastic Therapy Market Forecast
10.4.4 Italy Anti-Neoplastic Therapy Market Forecast
10.4.5 Russia Anti-Neoplastic Therapy Market Forecast
10.5 Middle East & Africa Anti-Neoplastic Therapy Forecast by Region (2025-2030)
10.5.1 Egypt Anti-Neoplastic Therapy Market Forecast
10.5.2 South Africa Anti-Neoplastic Therapy Market Forecast
10.5.3 Israel Anti-Neoplastic Therapy Market Forecast
10.5.4 Turkey Anti-Neoplastic Therapy Market Forecast
10.5.5 GCC Countries Anti-Neoplastic Therapy Market Forecast
10.6 Global Anti-Neoplastic Therapy Forecast by Type (2025-2030)
10.7 Global Anti-Neoplastic Therapy Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Information
11.1.2 Amgen Inc. Anti-Neoplastic Therapy Product Offered
11.1.3 Amgen Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Amgen Inc. Main Business Overview
11.1.5 Amgen Inc. Latest Developments
11.2 AstraZeneca plc
11.2.1 AstraZeneca plc Company Information
11.2.2 AstraZeneca plc Anti-Neoplastic Therapy Product Offered
11.2.3 AstraZeneca plc Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 AstraZeneca plc Main Business Overview
11.2.5 AstraZeneca plc Latest Developments
11.3 Bayer AG
11.3.1 Bayer AG Company Information
11.3.2 Bayer AG Anti-Neoplastic Therapy Product Offered
11.3.3 Bayer AG Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Bayer AG Main Business Overview
11.3.5 Bayer AG Latest Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Anti-Neoplastic Therapy Product Offered
11.4.3 Johnson & Johnson Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Johnson & Johnson Main Business Overview
11.4.5 Johnson & Johnson Latest Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Information
11.5.2 Merck & Co., Inc. Anti-Neoplastic Therapy Product Offered
11.5.3 Merck & Co., Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Merck & Co., Inc. Main Business Overview
11.5.5 Merck & Co., Inc. Latest Developments
11.6 Pfizer Inc.
11.6.1 Pfizer Inc. Company Information
11.6.2 Pfizer Inc. Anti-Neoplastic Therapy Product Offered
11.6.3 Pfizer Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Pfizer Inc. Main Business Overview
11.6.5 Pfizer Inc. Latest Developments
11.7 F. Hoffmann-La Roche Ltd.
11.7.1 F. Hoffmann-La Roche Ltd. Company Information
11.7.2 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Product Offered
11.7.3 F. Hoffmann-La Roche Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.7.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Information
11.8.2 Eli Lilly and Company Anti-Neoplastic Therapy Product Offered
11.8.3 Eli Lilly and Company Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Eli Lilly and Company Main Business Overview
11.8.5 Eli Lilly and Company Latest Developments
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Teva Pharmaceutical Industries Ltd. Company Information
11.9.2 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Product Offered
11.9.3 Teva Pharmaceutical Industries Ltd. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.9.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Anti-Neoplastic Therapy Product Offered
11.10.3 Boehringer Ingelheim Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Boehringer Ingelheim Main Business Overview
11.10.5 Boehringer Ingelheim Latest Developments
11.11 Aspen Pharmacare Holdings Limited
11.11.1 Aspen Pharmacare Holdings Limited Company Information
11.11.2 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Product Offered
11.11.3 Aspen Pharmacare Holdings Limited Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Aspen Pharmacare Holdings Limited Main Business Overview
11.11.5 Aspen Pharmacare Holdings Limited Latest Developments
11.12 AbbVie Inc.
11.12.1 AbbVie Inc. Company Information
11.12.2 AbbVie Inc. Anti-Neoplastic Therapy Product Offered
11.12.3 AbbVie Inc. Anti-Neoplastic Therapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 AbbVie Inc. Main Business Overview
11.12.5 AbbVie Inc. Latest Developments
12 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る